Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: Phase I and pharmacologic study

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 17-23

  Van Gijn, Roel ^a   Ten Bokkel Huinink, Wim W ^a   Rodenhuis, Sjoerd ^a   Vermorken, Jan B ^b,c   Van Tellingen, Olaf ^a   Rosing, Hilde ^a   Van Warmerdam, Laurence J C ^a   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Intoplicine; Pharmacokinetics; Phase I

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; INTOPLICINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG HALF LIFE; FEMALE; HEPATIC COMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033061497     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00003     Document Type: Article

References (17)

1. Riou JF, Fossé P, Nguyen CH, et al. Intoplicine and its derivatives, a new class of antitumour agents inhibiting both topoisomerase I and II activities. Cancer Res 1993; 53: 5987-93.
2. Morjani H, Riou JF, Nabiev 1, Lavelle F, Manfait M. Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. Cancer Res 1993; 53: 4784-90.
3. Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996; 39: 109-12.
4. RP60475 Intopoline. Investigator's brochure, Rhône-Poulene Rorer Company, Antony Cedex, France 1991.
5. Bissery MC, André S, Renard A, Montay G, Bayssas M, Lavelle F. Efficacy, pharmacokinetics and distribution of RP 60475. Ann Oncol 1992; Suppl 1: 94.
6. Bissery MC, Nguyen CB, Bisagni E, Vrignaud P, Lavelle F. Antitumour activity of intoplicine, a new benzo-pyridoindole: evaluation against solid tumours and leukaemia in mice. Invest New Drugs 1993; 11: 263-77.
7. Eckhardt JR, Burris III HR, Kuhn JG, et al. Activity of intoplicine, a new DNA topoisomerase I and II inhibitor, against human tumour colony-forming units in vitro. J Natl Cancer Inst 1994; 86: 30-3.
8. Kanc BJ, Eckhardt JR. Burris HA, et al. Phase I clinical and pharmacokinetic trial of intoplicine. Proc Am Soc Clin Oncol 1993; 12: A424.
9. van Gijn R. De Graaff-Teulen MJA, van Tellingen O. Beijnen JH. Chemical stability of the new antitumour agent intoplicine in infusion fluids. J Pharm Biomed Anal 1993; 11: 1353-6.
10. van Gijn R, Kuijs S, Rosing H, et al. Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 1993; 11: 1345-8.
11. van Gijn R, Rosing H, ten Bokkel Huinink WW, et al. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr 1993; 614: 299-306.
12. Gibaldi M, Perrier D, eds. Pharmacokinetics. 2nd edn. New York: Marcel Dekker 1982.
13. Strauss G, Pagani O, Sessa C, lund B. Cavalli F, Hansen H. A phase I study of intoplicine administered on a daily × 5 schedule. Proc Am Ass Cancer Res 1993; 34: 1378 (abstr).
14. Abigerges D, Armand JP, Chabot CG. et al. Phase I and pharmacology study of intoplicine, a novel topoisomerase I and II inhibitor, in cancer patients. Anti-Cancer Drugs 1996; 7: 166-74.
15. Poddevin B, Riou JF, Lavelle F Pommier F. Dual topoisomerase I and II inhibition by intoplicine, a new antitumour agent in early clinical trials. Mol Pharmacol 1993; 4: 767-74.
16. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986; 70: 73-80.
17. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase T clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990; 82: 1321-7.